Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W
Division of Hematology/Oncology, UCLA Medical Center, Los Angeles, CA 90095, USA.
Tech Coloproctol. 2004 Nov;8 Suppl 1:s50-2. doi: 10.1007/s10151-004-0110-4.
To evaluate the activity and safety of bevacizumab when given with standard 5FU/leukovorin (LV) regimens in patients with metastatic colorectal cancer who have failed irinotecan and oxaliplatin-based treatments.
Bevacizumab was given at 5 mg/kg as an IV infusion every 2 weeks. Patients received 5FU according to Roswell Park or the de Gramont regimen.
Nineteen patients enrolled, median age 60, median PS: 1. Most common toxicity attributable to bevacizumab was mild hypertension, epistaxis and mild proteinuria; 1 patient had a CNS haemorrhage. The median number of cycles was 1 (8 weeks). Clinical benefit as disease stabilisation lasting 2-6 months was noted in 9 patients, whereas 10 progressed (median f/u: 5 months). TTP was 16 weeks, and the overall survival has not been reached (24+ weeks).
Bevacizumab may result in growth arrest and clinical benefit in a substantial proportion of patients with colorectal cancer and no alternative treatment.
评估贝伐单抗与标准5-氟尿嘧啶/亚叶酸钙（LV）方案联合应用于伊立替康和奥沙利铂治疗失败的转移性结直肠癌患者时的活性和安全性。
贝伐单抗以5mg/kg静脉输注，每2周一次。患者根据罗斯韦尔帕克或德格拉蒙方案接受5-氟尿嘧啶治疗。
19例患者入组，中位年龄60岁，中位体能状态（PS）：1。贝伐单抗引起的最常见毒性为轻度高血压、鼻出血和轻度蛋白尿；1例患者发生中枢神经系统出血。中位周期数为1（8周）。9例患者出现疾病稳定持续2至6个月的临床获益，而10例进展（中位随访：5个月）。疾病进展时间（TTP）为16周，总生存期尚未达到（24 +周）。
贝伐单抗可能使相当一部分无可替代治疗方案的结直肠癌患者出现生长停滞并获得临床获益。
